Water diuretic effect of intravenously administered 9-deoxo-16, 16-dimethyl-9-methylene-PGE2 in conscious man.
The stable prostaglandin analogue 9-deoxo-16, 16-dimethyl-9-methylene-PGE2 (9-methylene-PGE2) was infused intravenously (0.5 ml/min) in the dosage of 20 micrograms/min for 2 h in conscious euhydrated man. The administration of 9-methylene-PGE2 rapidly induced an increase in urine flow (from 1.2 +/- 0.07 to 5.35 +/- 1.07 ml/min) concomitantly with a decrease in urine osmolality (from 827 +/- 40 to 193 +/- 44 mOsm/kg). Parallel to this tubular reabsorption of sodium (Na+), calcium (Ca2+) and magnesium (Mg3+) increased and that of potassium (K+) decreased as shown by a reduction in the clearance for respective ion divided by the clearance of inulin. Apparently the water diuresis was mediated by an inhibition of arginine vasopressin's (AVP) antidiuretic effect. The mechanism behind the increase in renal tubular reabsorbtion of Na+ could possibly be a 9-methylene-PGE2 mediated modulation of the renal aldosterone effect. However the protocol followed did not provide any evidence for this, or any other explanation of the observed renal retention of Na+, Ca2+ and Mg2+. The results reported here indicate that 9-methylene-PGE2 may have a future use as a water diuretic agent in patients suffering from water retention and dilutional hyponatraemia such as seen in the syndrome of inappropriate antidiuretic hormone (AVP) release commonly known as SIADH or Schwartz-Bartter's Syndrome.
D015064:16,16-Dimethylprostaglandin E2 / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology*; D000328:Adult; D001833:Body Temperature Regulation / Q000187:drug effects; D001834:Body Water / Q000187:drug effects*; D002118:Calcium / Q000378:metabolism; D008401:Gas Chromatography-Mass Spectrometry; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D008274:Magnesium / Q000378:metabolism; D008297:Male; D009994:Osmolar Concentration; D010710:Phosphates / Q000378:metabolism; D011188:Potassium / Q000378:metabolism; D011459:Prostaglandins E, Synthetic / Q000494:pharmacology*; D012079:Renal Circulation / Q000187:drug effects; D012964:Sodium / Q000378:metabolism; D014546:Urinary Catheterization
D010710:Phosphates; D011459:Prostaglandins E, Synthetic; C025505:meteneprost; D012964:Sodium; D008274:Magnesium; D015064:16,16-Dimethylprostaglandin E2; D011188:Potassium; D002118:Calcium